Grant of Options
29 July 2019
Concepta plc ("Concepta" or the "Company") (AIM: CPT), the innovative UK personalised healthcare company and developer of the proprietary self-test platform ("myLotus®") and suite of emerging test products targeting the mobile health market with a primary focus on women's fertility and hormone health, announces that the Company has today granted share options over a total of 1,203,900 ordinary shares of 2.5 pence each in the capital of the Companty (the "New Share Options"). The New Share Options represent approximately 0.45% of the issued ordinary share capital and have been awarded to Chief Operating Officer David Darrock under the EMI Share Option Scheme at exercise prices of 4p and 3p, respectively, per share.
The Options shall time vest as follows:
500,000 New Share Options of 4p will vest in 3 tranches : 166,667 on 29th January 2020, 166,667 on 29th January 2021 and 166,666 on 29th January 2022 and 703,900 New Share Options of 3p will vest equally in three tranches annually over the next 3 years 234,634 on 29th January 2020, 234,633 on 29th January 2021 and 234,633 on 29th January 2022 .
Details of the person discharging managerial responsibilities / person closely associated
David John Darrock
Reason for the notification
Chief Operating Officer
Initial notification /Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Options under the Company's EMI Share Option Scheme
Nature of the transaction
Grant of Options
Price(s) and volume(s)
- Aggregated volume
£0.03 and £0.04 as above
Date of the transaction
29 July 2019
Place of the transaction
London Stock Exchange, AIM
The Company www.conceptaplc.com, Product: www.mylotus.com
Tel +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Tel: +44 (0)20 368 3550
Novum Securities (Broker)
+44 (0) 20 7399 9400
Concepta Plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalised mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained.
myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.
myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.